Skip to main content
Erschienen in: BMC Pregnancy and Childbirth 1/2022

Open Access 01.12.2022 | Research

Prediction of small-for-gestational-age neonates at 33–39 weeks’ gestation in China: logistic regression modeling of the contributions of second- and third-trimester ultrasound data and maternal factors

verfasst von: Danping Xu, Xiuzhen Shen, Heqin Guan, Yiyang Zhu, Minchan Yan, Xiafang Wu

Erschienen in: BMC Pregnancy and Childbirth | Ausgabe 1/2022

Abstract

Objectives

A screening model for prediction of small-for-gestational-age (SGA) neonates (SGAp) was established by logistic regression using ultrasound data and maternal factors (MF). We aimed to evaluate the ability of SGAp as well as abdominal circumference (AC) and estimated fetal weight (EFW) measurements to predict SGA neonates at 33–39 weeks’ gestation.

Methods

This retrospective study evaluated 5298 singleton pregnancies that had involved three ultrasound examinations at 21+0–27+6, 28+0–32+6, and 33+0–39+6 weeks. All ultrasound data were transformed to MoM values (multiple of the median). Multivariate logistic regression was used to analyze the correlation between SGA status and various variables (ultrasound data and MF) during pregnancy to build the SGAp model. EFW was calculated according to the Hadlock formula at 33–39 weeks of gestation. The predictive performance of SGAp, AC MoM value at 33+0–39+6 weeks (AC-M), EFW MoM value (EFW-M), EFW-M plus MF, AC value at 33+0–39+6 weeks (AC), AC growth velocity, EFW, and EFW plus MF was evaluated using ROC curves. The detection rate (DR) of SGA neonate with SGAp, AC-M, EFW-M, and EFW-M plus MF at false positive rate (FPR) of 5% and 10%, and the FPR at DR of 85%, 90%, and 95% were observed.

Results

The AUCs of SGAp, AC-M, EFW-M, EFW-M plus MF, AC, AC growth velocity, EFW, and EFW plus MF for SGA neonates screening were 0.933 (95%CI: 0.916–0.950), 0.906 (95%CI: 0.887–0.925), 0.920 (95%CI: 0.903–0.936), 0.925 (95%CI: 0.909–0.941), 0.818 (95%CI: 0.791–0.845), 0.786 (95%CI: 0.752–0.821), 0.810 (95%CI: 0.782–0.838), and 0.834 (95%CI: 0.807–0.860), respectively. The screening efficiency of SGAp, AC-M, EFW-M, and EFW-M plus MF are significantly higher than AC, AC growth velocity, EFW, and EFW plus MF. The DR of SGAp, AC-M, EFW-M, and EFW-M plus MF for SGA neonates were 80.4%, 69.6%, 73.8% and 74.3% at 10% FPR. The AUCs of SGAp, AC-M, EFW-M, and EFW-M plus MF 0.950 (95%CI: 0.932–0.967), 0.929 (95%CI: 0.909–0.948), 0.938 (95%CI: 0.921–0.956) and 0.941 (95%CI: 0.924–0.957), respectively for screening SGA neonates delivered within 2 weeks after the assessment. The DR for these births increased to 85.8%, 75.8%, 80.0%, and 82.5%, respectively.

Conclusion

The rational use of ultrasound data can significantly improve the prediction of SGA statuses.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Small-for-gestational-age (SGA) status is defined by birth weight below the 10th percentile of the mean weight for the same gestational age (GA) or two standard deviations below the mean weight for the same GA. The SGA status is associated with more risk factors and more complications. SGA is a crucial predictive index of surgical intervention for congenital heart disease (CHD), and the coexistence of SGA and CHD is more likely to lead to death than either alone [1, 2]. One study published in 1997 reported that the incidence of suspected fetal asphyxia was threefold (6%-8%) higher in SGA fetuses than in non-SGA fetuses [3]. The perinatal mortality rate of SGA fetuses was high, and survivors showed adverse neurocognitive development leading to non-severe neurological dysfunction [4, 5].
Several approaches have been used to predict SGA neonates during pregnancy, some of which are summarized below. (1) Estimated fetal weight (EFW) measurements [68]: Most EFW formulas show a strong correlation between the predicted weight and actual birth weight (r > 0.9, 19/21 formulas) [6]. The area under the curve (AUC) for predictions based on EFW measurements in the mid-trimester or third-trimester ultrasound was 0.69 ~ 0.72 and 0.79, respectively [9, 10]. Ciobanu et al. showed that the AUC of EFW measurements was 0.883 at 35 and 36 weeks of gestation, while the AUC for births that occurred within two weeks of the evaluation could be as high as 0.933 [11]. (2) Ultrasound data [9, 1113]: The AUC of the abdominal circumference (AC) growth velocity between 20 and 36 weeks was 0.808, while the AUC for births within two weeks of the evaluation was 0.884 [11]. However, many ultrasound data alone showed poor performance for predicting neonatal SGA [9, 12, 13]. (3) Biomarker evaluations: Biomarkers alone were not perfect for neonatal SGA prediction [1416]. But Biomarkers and EFW in conjunction with maternal factors (MF) show good predictive value [16].
Therefore, this study aims to improve the detection rate (DR) of neonatal SGA screening by constructiong a SGA screening model (SGAp) through multivariate logistic regression modeling without increasing the cost of pregnancy examination.

Methods

Study design overview

This was a retrospective study. A total of 21 092 pregnant women gave birth in Taizhou hospital from January 2017 to March 2021. Figure 1 outlines the data collection process and 5 298 pregnant women were included in this study. The inclusion criteria were single live births at 33 to 41 weeks’ gestation, and a history of at least three ultrasonographic examinations at 21+0–27+6, 28+0–32+6, and 33+0–39+6 weeks at our hospital. Considering the errors caused by different hospitals with different doctors and instruments, the reports form different hospitals were excluded. Maternal characteristics, diseases during the pregnancy, ultrasound data, and delivery information were recorded when the pregnant women came to our hospital for delivery.
The GA of the fetus was determined by the last menstrual period and the crown-to-rump length (CRL) of the fetuses at 11–14 weeks [17]. When the GAs determined by both methods were less than 1 week apart, the last menstrual period was chosen to determine the GA. However, when the GAs determined by both methods were more than 1 week apart, the GA based on ultrasound measurements was included in the analyses. All ultrasound examinations were performed by examiners with a certificate from a medical practitioner. In China, pregnant women younger than 35 weeks were required to participate in the first- and second-trimester screening or NIPT screening, and older and high-risk pregnant women were required to undergo amniocentesis to eliminate major fetal chromosome diseases. When pregnant women from 33 to 40 weeks of gestation came to our hospital for ultrasound appointment, we introduced the intention of this study to them and sign an informed consent form. All pregnant women, admitted to our hospital for delivery, were informed that all information about their pregnancy might be used anonymously in the future and signed informed consent. The study was approved by Taizhou Ethics Committee.

Sample size calculation

The previously published report showed expected sensitivity towards EFW for detecting neonatal SGA to be 60.6% and specificity 87.6%, whereas for AC this rate was 64.4% and 83.5%, respectively, between 33+0 ~ 35+6 gestational weeks [18]. The sample size was calculated by software according to the above rates and a usable sample size of 88 patients was required in the anomalies group, with an allowable error of 0.1 in a two-tailed test with p < 0.05.

Maternal characteristics

All pregnant women were Chinese. Maternal age, height, weight, body mass index (BMI), pregnancy history (the number of pregnancy, number of production, scarred uterus), and disease history during pregnancy were recorded.
Hypertension, diabetes, pre-eclampsia, vaginal inflammation (such as bacterial vaginosis, candida vaginosis, streptococcus lactis vaginitis, trichomonas vaginitis), viral infection (HBV, syphilis, HPV, etc.), intrahepatic cholestasis, thyroid dysfunction, abnormal placental shape, placental hypofunction, anemia or pelvic adhesionism during pregnancy might affect the health and development of the fetuses. As we all knew, pre-eclampsia was a type of hypertensive disorder of pregnancy that could lead to conditions such as fetal growth restriction and placental abruption. Gestational diabetes could cause fetal overgrowth. Vaginal inflammation might lead to infection, causing pelvic inflammatory disease and intrauterine infection. placental hypofunction (placental aging) might lead to hypoxia of the fetuses and even to the arrest of placental development.
The delivery process was also well-documented, and the mode of delivery, fetal distress, vaginal laceration, and the use of low forceps was recorded.

Neonatal characteristics

Neonatal sex, weight, GA at birth, and neonatal asphyxia were recorded. According to the latest Chinese standards [19], a fetus weighing less than the 10th percentile or more than 90th percentile of the GA (≤ 36 weeks), and weighing less than 2500 g or more than 4000 g after term is considered a SGA neonate or large for GA (LGA) neonate, respectively. Neonates that do not meet the criteria for SGA and LGA statuses are called appropriate for gestational age (AGA) neonates.

Ultrasonic data collection

All pregnant women had undergone ultrasound examinations at 20+0–27+6 weeks, 28+0–32+6 weeks, and 33+0–39+6 weeks. Head circumference (HC), abdominal circumference (AC), femur length (FL), biparietal diameter (BPD), occipitofrontal diameter (OFD), amniotic fluid index (AFI), placebtak thickness (PT), the ratio of systolic velocity / diastolic velocity of umbilical artery blood flow (S/D), pulsatile index of umbilical artery (PI), resistance index of umbilical artery blood flow (RI) were recorded. The 10th, 50th and 90th percentile values of all ultrasound data were counted according to gestational age.

Transformed ultrasound data according to GA

All ultrasound data in this paper were transformed according to the local median of gestational ages, that was to say MoM values (multiple of the median). The reasons were as follows: At each GA, ultrasound data were not normally distributed. And each region had distinct differences due to climate and diet differences (e.g., northern and southern China). Therefore, MoM values were more appropriate than Z-Score when ultrasound data were transformed according to GA in this region.

Estimated fetal weight (EFW)

The combination of AC, FL, BPD and HC yields a variety of formulas for calculating EFW [6]. According to the ultrasonic data from 33+0–39+6 weeks’ gestation, EFW was calculated respectively and finally converted into EFW MoM values (EFW-M) according to GA. ROC curve analysis showed that the formula created by Hadlock (1985) based on AC, FL and HC was the most suitable for this paper (Data not displayed).

AC growth velocity

Previous article showed that AC growth velocity was better than EFW growth velocity for prediction of SGA neonate between 20 and 36 weeks [11]. The calculation method of AC growth velocity referred to this article.

A SGA predictor (SGAp) model

Multivariate logistic regression was used to establish a SGAp model. Univariate logistic regression analysis was used to analyze the relationship between related variables and SGA neonates. The predicted SGA values were recalculated based on this model for all fetal conditions. The DR of SGA neonates was observed at 5% and 10% FPR. At the same time, The FPR of SGA was observed at the DR of 85%, 90% and 95%.

Statistical analysis

Data were described in terms of medians/interquartile range (IQR) for continuous variables or numbers (n and %) for categorical variable. Mann–whitney U test, rank sum test or Chi-square test were used to compare differences between groups. Receiver operating characteristic (ROC) curves analysis was performed to evaluate the power of SGAp, AC MoM value at 33+0–39+6 weeks (AC-M), EFW-M, EFW-M plus MF, AC value at 33+0–39+6 weeks (AC), AC growth velocity, EFW, and EFW plus MF to discriminate SGA neonates. A p < 0.05 was considered to be significant.

Results

Patient characteristics

A total of 5 298 pregnancies with GAs of 33–41 weeks at birth were included in the study (Fig. 1 shows the inclusion process). The study population included 214 SGA (4.1%), 4828 AGA (91.1%), and 256 LGA (4.8%) neonates. The AGA and LGA neonates, collectively referred to as non-SGA neonates, served as the control group in this study. Basic information on the pregnant women, disease history during pregnancy, delivery, and newborn information are shown in Table 1. Weight, height, and BMI during pregnancy, proportion of boys, gestational week of delivery, and the proportion of streptococcal vaginitis in the women who delivered SGA neonates were significantly lower than those in women who delivered AGA and LGA neonates. On the other hand, the proportions of cesarean deliveries and patients with chronic hypertension and preeclampsia among women who delivered SGA neonates were significantly higher than those among women who delivered AGA and LGA neonates. Correlation analysis showed that SGA was correlated with maternal height, weight, BMI, fetal sex, and gestational disease history (streptococcus lactis vaginitis, gestational hypertension, preeclampsia, intrahepatic cholestasis during pregnancy), while LGA was associated with maternal age, height, weight, BMI, number of pregnancies, number of deliveries, baby sex, and gestational disease history (gestational diabetes, bacterial vaginitis, anemia).
Table 1
The characteristics of pregnant women, their pregnancies and neonates
Characteristics
SGA
AGA
LGA
P
(n = 214)
(n = 4828)
(n = 256)
Maternal characteristics
 Age (years)
29 (26–33)
30 (26–33)
31 (28–34)**
 < 0.001
 Predelivery weight (kg)
64 (59–72)**
68 (63–74)
74 (69–80)**
 < 0.001
 Height (cm)
158 (155–160)**
160 (157–163)
160 (158–164)**
 < 0.001
 BMI
25.8 (23.6–28.7)**
26.6 (24.8–28.9)
28.8 (26.6–30.7)**
 < 0.001
 The number of pregnancy
2 (1–3)
2 (1–3)
2 (1–4)**
0.014
 The number of delivery
0 (0–1)
0 (0–1)
1 (0–1)*
0.004
Newborn information
 Baby gender
  Boy
85 (39.7%)**
2520 (52.2%)
183 (71.5%)**
 < 0.001
  Girl
129 (60.3%)
2308 (47.8%)
73 (28.5%)
 Gestational age at birth (weeks)
37 (37–38)**
38 (37–39)
39 (39–40)**
 < 0.001
 Premature infant (33–36 weeks)
45 (21.0%)**
418 (8.7%)
1 (0.4%)**
 < 0.001
 The birth weight of the baby
2355 (2195–2440)**
3250 (2990–3510)
4160 (4070–4300)**
 < 0.001
 Neonatal asphyxia
0 (0%)
15 (0.3%)
1 (0.4%)
0.921
The delivery information
 Scarred uterus
27 (12.6%)
756 (15.7%)
47 (18.4%)
0.233
 Caesarean section
90 (42.1%)**
1362 (28.2%)
95 (37.1%)**
 < 0.001
 Colpoperineal laceration
71 (33.1%)**
2449 (50.8%)
102 (39.9%)**
 < 0.001
  Grade I vaginal laceration
60 (28.0%)*
1760 (36.5%)
58 (22.7%)**
 < 0.001
  Grade II vaginal laceration
11 (5.1%)**
689 (14.3%)
44 (17.2%)
 < 0.001
 Fetal distress in uterus
29 (13.6%)
554 (11.5%)
26 (10.2%)
0.511
 Low forceps delivery
5 (2.3%)
249 (5.2%)
18 (7.0%)
0.069
Diseases of pregnancy
 vaginal inflammation
25 (11.7%)
559 (11.6%)
36 (14.1%)
0.484
  Bacterial vaginosis
6 (2.8%)
111 (2.3%)
15 (5.9%)**
 < 0.001
  Candida vaginosis
20 (9.3%)
310 (6.4%)
18 (7.0%)
0.229
  Streptococcus lactis vaginitis
2 (0.9%)*
201 (4.2%)
14 (5.5%)
0.035
  Trichomonas vaginitis
1 (0.5%)
6 (0.1%)
1 (0.4%)
0.269
 Gestational diabetes mellitus
46 (21.5%)
1088 (22.5%)
86 (33.6%)**
 < 0.001
 Hypertension
19 (8.9%)**
189 (3.9%)
8 (3.1%)
 < 0.001
  Pregnancy hypertension
12 (5.6%)
168 (3.5%)
6 (2.3%)
0.148
  Chronic hypertension
7 (3.3%)**
21 (0.4%)
2 (0.8%)
 < 0.001
 Placental hypofunction
30 (14.0%)
554 (11.5%)
22 (8.6%)
0.177
 Preeclampsia
29 (13.6%)**
118 (2.4%)
7 (2.7%)
 < 0.001
  Mild preeclampsia
12 (5.6%)**
81 (1.7%)
7 (2.7%)
 < 0.001
  Serious preeclampsia
17 (7.9%)**
37 (0.8%)
0 (0%)
 < 0.001
 Intrahepatic cholestasis during pregnancy
8 (3.7%)
79 (1.6%)
2 (0.8%)
0.076
 Thyroid dysfunction
11 (5.1%)
411 (8.5%)
23 (9%)
0.368
 Virus infection
  HBV
5 (2.3%)
111 (2.3%)
6 (2.3%)
0.998
  Syphilis
1 (0.5%)
26 (0.5%)
1 (0.4%)
0.943
  HPV
0 (0%)
12 (0.2%)
1 (0.4%)
0.688
 Abnormal shape of placenta
19 (8.9%)
343 (7.1%)
18 (7.0%)
0.678
 Pelvic adhesion
3 (1.4%)
97 (2.0%)
6 (2.3%)
0.761
 Anemia
18 (8.4%)
562 (11.6%)
40 (15.6%)
0.048
Data are given as n (%) or median (interquartile range). *P < 0.05, **P < 0.001

Ultrasound data at different gestational weeks

All pregnant women had undergone ultrasound examinations at 20+0–27+6 weeks, 28+0–32+6 weeks, and 33+0–39+6 weeks. In China, the most accurate detection time for abnormal ultrasound findings is 23–25 weeks, so a large number of people choose to undergo ultrasound at 24 weeks’ gestation. All data were grouped according to GA and described as median, 10th, and 90th percentiles (Table 2). After all data were MoM value-transformed, rank-sum test analysis showed that the BPD, OFD, HC, FL, AC, and AFI of SGA fetuses were significantly lower than those of AGA and LGA fetuses at 20+0–27+6, 28+0–32+6, and 33+0–39+6 weeks’ gestation (Table 3).
Table 2
the 10th percentile, 50th percentile and 90th percentile values of BPD, OFD, HC, FL, AC, AFI, S/D, PI, RI and PT for gestational age
GA
N
BPD
OFD
HC
FL
AC
10th
50th
90th
10th
50th
90th
10th
50th
90th
10th
50th
90th
10th
50th
90th
21+0 ~ 21+6
11
48
52
55
62
66
69
177
190
205
33
37
38
158
167
179
22+0 ~ 22+6
56
53
55
59
67
71
75
196
207
218
37
40
42
171
183
193
23+0 ~ 23+6
887
54
59
63
70
74
79
205
218
230
39
42
45
178
192
206
24+0 ~ 24+6
3549
57
60
64
72
76
80
213
223
233
41
43
46
187
198
209
25+0 ~ 25+6
684
59
62
66
75
79
83
221
231
242
43
45
48
194
206
217
26+0 ~ 26+6
80
61
65
68
77
82
86
229
240
252
44
47
50
197
214
224
27+0 ~ 27+6
31
58
68
73
74
87
91
218
254
264
42
50
52
195
226
240
28+0 ~ 28+6
686
69
72
76
87
91
95
255
265
277
51
53
56
230
242
255
29+0 ~ 29+6
1200
72
75
79
90
94
98
264
275
287
53
55
58
241
253
267
30+0 ~ 30+6
1708
74
77
81
92
96
101
272
282
293
55
57
60
250
262
275
31+0 ~ 31+6
915
76
80
83
95
99
104
279
289
301
57
59
62
259
273
285
32+0 ~ 32+6
789
78
82
86
97
102
106
286
297
309
59
61
63
267
282
295
33+0 ~ 33+6
589
80
84
88
100
104
109
292
304
317
60
63
66
278
293
307
34+0 ~ 34+6
1333
82
86
90
102
106
110
300
310
321
63
65
68
288
302
317
35+0 ~ 35+6
1386
85
88
92
104
108
112
306
316
328
64
67
69
297
312
327
36+0 ~ 36+6
1165
86
90
93
106
110
113
311
321
333
66
69
71
306
320
335
37+0 ~ 37+6
574
88
92
95
108
112
115
316
327
338
67
70
72
314
330
345
38+0 ~ 38+6
206
88
92
96
108
112
116
318
329
342
68
71
74
320
334
351
39+0 ~ 39+6
45
90
94
98
109
114
118
322
336
347
69
72
74
327
342
358
GA
N
AFI
S/D
PI
RI
PT
10th
50th
90th
10th
50th
90th
10th
50th
90th
10th
50th
90th
10th
50th
90th
21+0 ~ 21+6
11
95
116
127
2.95
3.11
3.80
1.03
1.11
1.29
0.66
0.68
0.74
21
22
25
22+0 ~ 22+6
56
94
119
141
2.46
2.96
3.59
0.90
1.08
1.26
0.60
0.67
0.72
21
24
28
23+0 ~ 23+6
887
92
119
157
2.38
3.05
3.84
0.85
1.08
1.28
0.58
0.67
0.74
20
25
31
24+0 ~ 24+6
3549
96
119
147
2.46
3.00
3.65
0.88
1.06
1.24
0.59
0.67
0.73
22
26
30
25+0 ~ 25+6
684
96
119
148
2.46
2.96
3.57
0.88
1.05
1.22
0.59
0.66
0.72
22
26
31
26+0 ~ 26+6
80
95
117
149
2.3
2.84
3.50
0.81
1.02
1.18
0.57
0.65
0.71
23
27
32
27+0 ~ 27+6
31
96
110
134
2.38
2.69
3.30
0.86
0.99
1.14
0.58
0.63
0.70
24
28
31
28+0 ~ 28+6
686
94
115
144
2.18
2.68
3.24
0.77
0.95
1.14
0.54
0.63
0.69
25
29
33
29+0 ~ 29+6
1200
92
112
143
2.14
2.62
3.10
0.75
0.94
1.09
0.53
0.62
0.68
26
30
34
30+0 ~ 30+6
1708
90
110
141
2.09
2.53
2.95
0.73
0.91
1.06
0.52
0.61
0.66
27
31
35
31+0 ~ 31+6
915
87
108
143
2.05
2.49
2.93
0.71
0.90
1.05
0.51
0.60
0.66
27
31
36
32+0 ~ 32+6
789
85
105
136
2.01
2.46
2.88
0.69
0.89
1.03
0.50
0.59
0.65
28
32
37
33+0 ~ 33+6
589
78
102
136
1.97
2.38
2.84
0.68
0.86
1.02
0.49
0.58
0.65
29
33
38
34+0 ~ 34+6
1333
80
101
134
1.92
2.32
2.79
0.65
0.84
1.02
0.48
0.57
0.64
29
33
38
35+0 ~ 35+6
1386
77
100
130
1.91
2.26
2.75
0.64
0.81
1.00
0.48
0.56
0.64
30
34
38
36+0 ~ 36+6
1165
78
99
130
1.88
2.24
2.73
0.63
0.81
0.99
0.47
0.55
0.63
30
34
39
37+0 ~ 37+6
574
76
98
135
1.82
2.18
2.66
0.60
0.78
0.97
0.45
0.54
0.62
31
35
39
38+0 ~ 38+6
206
71
99
135
1.84
2.16
2.61
0.61
0.78
0.98
0.46
0.54
0.62
31
35
38
39+0 ~ 39+6
45
63
90
125
1.82
2.11
2.52
0.61
0.77
0.96
0.45
0.53
0.61
31
35
39
GA Gestational age, BPD Biparietal diameter, OFD Occipitofrontal diameter, HC Head circumference, FL Femur length, AC Abdomen circumference, AFI Amniotic fluid index, Umbilical arterial flow, S/D Ratio of fetal umbilical artery systolic to diastolic blood pressure, PI Pulsatile index, RI Resistance index, PT The thickness of the placenta
Table 3
The BPD, OFD, HC, FL, AC, AFI, S/D, PI, RI MoM values were converted according to gestational age
GA
Parameters
SGA
AGA
LGA
P
(n = 214)
(n = 4828)
(n = 256)
21+0 ~ 27+6
BPD
0.98 (0.95–1.00)**
1.00 (0.97–1.03)
1.02 (0.98–1.05)**
 < 0.001
OFD
0.97 (0.94–1.00)**
1.00 (0.97–1.03)
1.01 (0.99–1.04)**
 < 0.001
HC
0.98 (0.95–1.00)**
1.00 (0.98–1.02)
1.02 (0.99–1.04)**
 < 0.001
FL
0.98 (0.95–1.00)**
1.00 (0.98–1.04)
1.02 (1.00–1.05)**
 < 0.001
AC
0.98 (0.94–1.00)**
1.00 (0.97–1.03)
1.03 (1.00–1.06)**
 < 0.001
AFI
0.95 (0.84–1.06)**
1.00 (0.89–1.12)
1.03 (0.94–1.14)**
 < 0.001
S/D
1.01 (0.89–1.16)
1.00 (0.90–1.11)
0.97 (0.86–1.04)**
 < 0.001
PI
1.00 (0.90–1.11)
1.00 (0.91–1.09)
0.98 (0.88–1.05)**
 < 0.001
RI
1.00 (0.94–1.07)
1.00 (0.94–1.04)
0.99 (0.91–1.02)**
 < 0.001
PT
0.96 (0.88–1.04)**
1.00 (0.92–1.08)
1.04 (0.96–1.12)**
 < 0.001
28+0 ~ 32+6
BPD
0.96 (0.94–0.99)**
1.00 (0.98–1.03)
1.01 (1.00–1.05)**
 < 0.001
OFD
0.97 (0.94–0.99)**
1.00 (0.98–1.02)
1.02 (0.99–1.04)**
 < 0.001
HC
0.96 (0.95–0.99)**
1.00 (0.98–1.02)
1.02 (1.00–1.04)**
 < 0.001
FL
0.97 (0.95–1.00)**
1.00 (0.98–1.03)
1.02 (1.00–1.05)**
 < 0.001
AC
0.95 (0.93–0.98)**
1.00 (0.98–1.02)
1.04 (1.01–1.06)**
 < 0.001
AFI
0.98 (0.82–1.12)*
1.00 (0.89–1.13)
1.07 (0.97–1.23)**
 < 0.001
S/D
1.05 (0.96–1.14)**
1.00 (0.90–1.09)
0.96 (0.87–1.06)**
 < 0.001
PI
1.05 (0.96–1.14)**
1.00 (0.89–1.09)
0.96 (0.86–1.05)**
 < 0.001
RI
1.03 (0.97–1.08)**
1.00 (0.93–1.05)
0.97 (0.90–1.03)**
 < 0.001
PT
0.97 (0.90–1.06)
1.00 (0.93–1.06)
1.03 (0.97–1.12)**
 < 0.001
33+0 ~ 39+6
BPD
0.95 (0.93–0.98)**
1.00 (0.98–1.02)
1.02 (1.00–1.05)**
 < 0.001
OFD
0.96 (0.95–0.99)**
1.00 (0.98–1.02)
1.02 (1.00–1.04)**
 < 0.001
HC
0.96 (0.94–0.98)**
1.00 (0.98–1.02)
1.02 (1.01–1.04)**
 < 0.001
FL
0.96 (0.93–0.99)**
1.00 (0.98–1.02)
1.02 (1.00–1.03)**
 < 0.001
AC
0.93 (0.91–0.96)**
1.00 (0.98–1.02)
1.05 (1.03–1.07)**
 < 0.001
AFI
0.88 (0.77–1.01)**
1.00 (0.89–1.15)
1.11 (0.97–1.33)**
 < 0.001
S/D
1.05 (0.96–1.19)**
1.00 (0.91–1.11)
0.95 (0.86–1.06)**
 < 0.001
PI
1.05 (0.95–1.19)**
1.00 (0.88–1.12)
0.94 (0.82–1.05)**
 < 0.001
RI
1.04 (0.96–1.11)**
1.00 (0.91–1.07)
0.96 (0.87–1.04)**
 < 0.001
PT
0.97 (0.91–1.06)**
1.00 (0.94–1.06)
1.03 (1.00–1.11)**
 < 0.001
Data are given as median (interquartile range). GA Gestational age, BPD Biparietal diameter, OFD Occipitofrontal diameter, HC Head circumference, FL Femur length, AC Abdomen circumference, AFI Amniotic fluid index, Umbilical arterial flow, S/D Ratio of fetal umbilical artery systolic to diastolic blood pressure, PI Pulsatile index, RI Resistance index, PT The thickness of the placenta. *P < 0.05, **P < 0.001

Logistic regression modeling

Multivariate logistic regression modeling was conducted for all factors and ultrasound data after transformation. SGA neonates were represented by the dichotomous variable. It was found that the variables significantly correlated with the history of hypertension in pregnant women (X1, normal blood pressure = 0, gestational hypertension = 1, chronic hypertension = 2), preeclampsia (X2, no preeclampsia = 0, mild disease = 1, severe disease = 2), OFD MoM value at 21+0–27+6 weeks (OFD-M-[21, 27]) (X3), FL MoM value at 21+0–27+6 weeks (FL-M-[21, 27]) (X4), AC MoM value at 28+0–32+6 weeks (AC-M-[28, 32]) (X5), BPD MoM value at 33+0–39+6 weeks (BPD-M) (X6), FL MoM value at 33+0–39+6 weeks (FL-M) (X7), AC MoM value at 33+0–39+6 weeks (AC-M) (X8), AFI MoM value at 33+0–39+6 weeks (AFI-M) (X9). This model is called the SGA predictor (SGAp) (As shown in the Table 4). SGAp = -59.496–0.784X1-0.693X2-9.377X3 + 7.26X4 + 14.578X5 + 14.903X6 + 8.436X7 + 26.531X8 + 2.087X9.
Table 4
Multivariate Logistic regression model for SGA neonatal prediction
Characteristics
β
OR
95% CI
P
X1
Hypertension
-0.784
0.46
0.29–0.73
0.001
X2
Preeclampsia
-0.693
0.5
0.34–0.74
0.001
X3
OFD-M-[21, 27]
-9.377
0
0–0.01
 < 0.001
X4
FL-M-[21, 27]
7.26
1422
13.11–1.54*105
0.002
X5
AC-M-[28, 32]
14.578
2.14*106
1.11*104–4.16*108
 < 0.001
X6
BPD-M
14.903
2.97*106
1.04*104–8.44*108
 < 0.001
X7
FL-M
8.436
4609
11.24–1.89*106
0.006
X8
AC-M
26.531
3.33*1011
6.35*108–1.75*1014
 < 0.001
X9
AFI-M
2.087
8.06
3.44–18.91
 < 0.001
Constant
-59.496
0
 
 < 0.001
OFD-M-[21, 27], OFD MoM value at 21+0 ~ 27+6 weeks; FL-M-[21, 27], FL MoM value at 21+0 ~ 27+6 weeks; AC-M-[28, 32], AC MoM value at 28+0 ~ 32+6 weeks; BPD-M, BPD MoM value at 33+0 ~ 39+6 weeks; FL-M, FL MoM value at 33+0 ~ 39+6 weeks; AC-M, AC MoM value at 33+0 ~ 39+6 weeks; AFI-M, AFI MoM value at 33+0 ~ 39+6 weeks
Univariate logistic regression results also showed that these indexes were closely related to SGA neonates (Table 5). After MoM transformation, the ultrasound data were all between 0 and 2, which were close to the values of hypertension and eclampsia. Univariate logistic regression results illustrated that OFD-M-[21, 27], FL-M-[21, 27], AC-M-[28, 32], BPD-M, FL-M, AC-M had high risk factors for SGA (Table 5).
Table 5
Univariable Logistic regression for SGA neonatal prediction
Characteristics
OR
95% CI
P
Hypertension
0.43
0.30–0.62
 < 0.001
Preeclampsia
0.28
0.22–0.37
 < 0.001
OFD-M-[21, 27]
1.92*106
5.12*104–7.21*107
 < 0.001
FL-M-[21, 27]
2.95*105
1.13*107–7.68*109
 < 0.001
AC-M-[28, 32]
1.14*1015
2.03*1013–6.42*1016
 < 0.001
BPD-M
5.73*1016
6.96*1014–4.72*1018
 < 0.001
FL-M
6.43*1015
1.06*1014–3.90*1017
 < 0.001
AC-M
2.49*1020
2.43*1018–2.55*1022
 < 0.001
AFI-M
26.67
13.49–52.72
 < 0.001
OFD-M-[21, 27], OFD MoM value at 21+0 ~ 27+6 weeks; FL-M-[21, 27], FL MoM value at 21+0 ~ 27+6 weeks; AC-M-[28, 32], AC MoM value at 28+0 ~ 32+6 weeks; BPD-M, BPD MoM value at 33+0 ~ 39+6 weeks; FL-M, FL MoM value at 33+0 ~ 39+6 weeks; AC-M, AC MoM value at 33+0 ~ 39+6 weeks; AFI-M, AFI MoM value at 33+0 ~ 39+6 weeks

Prediction of SGA neonate by SGAp

The SGAp values, AC-M, EFW-M, and EFW-M plus MF of fetuses in the SGA group were significantly lower than those in the non-SGA group (Table 6). The SGAp values were significantly different between the SGA and non-SGA groups (Table 6). The AUCs of SGAp, AC-M, EFW-M, EFW-M plus MF, AC, AC growth velocity, EFW, and EFW plus MF are showed in Fig. 2. The screening efficiency of SGAp, AC-M, EFW-M, and EFW-M plus MF are significantly higher than AC, AC growth velocity, EFW, and EFW plus MF. The DR of SGAp, AC-M, EFW-M, and EFW-M plus MF for SGA neonate screening at 5% and 10% FPR are shown in Table 7. The corresponding FPR of these four indicators at 85%, 90%, and 95% DR are also shown in Table 8.
Table 6
The median of SGAp, AC-M, EFW-M and EFW-M plus maternal factors in SGA group and non-SGA group
Characteristic
SGA
non-SGA
p
median (IQR)
median (IQR)
SGA born at any stage (N)
214
5084
 
 SGAp
0.96 (-0.47–2.39)
5.14 (3.91–6.36)
 < 0.001
 AC-M
0.93 (0.91–0.96)
1.00 (0.98–1.03)
 < 0.001
 EFW-M
0.84 (0.79–0.90)
1.00 (0.95–1.06)
 < 0.001
 EFW-M plus MF
34.56 (33.42–36.12)
38.38 (37.19–39.56)
 < 0.001
SGA born within 2 weeks (N)
120
1459
 
 SGAp
0.61 (-0.79–1.93)
5.08 (3.91–6.35)
 < 0.001
 AC-M
0.93 (0.91–0.96)
1.00 (0.98–1.03)
 < 0.001
 EFW-M
0.82 (0.78–0.89)
1.01 (0.95–1.06)
 < 0.001
 EFW-M plus MF
34.35 (33.40–35.68)
38.43 (37.28–39.62)
 < 0.001
AC-M, AC MoM value at 33+0 ~ 39+6 weeks; EFW-M, EFW MoM value at 33+0 ~ 39+6 weeks; EFW-M plus MF, EFW-M plus maternal factors
Table 7
The DR of SGAp, AC-M, EFW-M, and EFW-M plus MF for SGA neonate screening at 5% and 10% FPR
Screening test
DR at 5% FPR (%)
DR at 10% FPR (%)
SGA born at any stage
 SGAp
70.6 (67.4–73.7)
80.4 (77.7–83.1)
 AC-M
60.7 (57.4–64.1)
69.6 (66.5–72.8)
 EFW-M
66.4 (63.1–69.6)
73.8 (70.8–76.8)
 EFW-M plus MF
67.8 (64.6–71.0)
74.3 (71.3–77.3)
SGA born within 2 weeks
 SGAp
74.2 (70.2–78.2)
85.8 (82.7–89.0)
 AC-M
66.7 (62.4–71.0)
75.8 (71.9–79.7)
 EFW-M
70.8 (66.7–75.0)
80.0 (76.3–83.7)
 EFW-M plus MF
72.5 (68.4–76.6)
82.5 (79.0–86.0)
AC-M, AC MoM value at 33+0 ~ 39+6 weeks; EFW-M, EFW MoM value at 33+0 ~ 39+6 weeks; EFW-M plus MF, EFW-M plus maternal factors
Table 8
The false positive rate necessary to achieve prediction of 85%, 90% and 95% SGA neonates
screening test
FPR for 85% DR (%)
FPR for 90% DR (%)
FPR for 95% DR (%)
SGA born at any stage
 SGAp
11.8 (11.3–12.3)
16.4 (15.9–17.0)
27.8 (27.1–28.4)
 AC-M
22.0 (21.4–22.6)
29.9 (29.3–30.6)
38.7 (38.1–39.4)
 EFW-M
19.3 (18.7–19.8)
24.4 (23.8–25.1)
33.1 (32.5–33.8)
 EFW-M plus MF
17.2 (16.7–17.8)
20.9 (20.3–21.5)
31.1 (30.5–31.8)
SGA born within 2 weeks
 SGAp
9.4 (8.6–10.2)
12.4 (11.5–13.3)
22.0 (20.9–23.1)
 AC-M
13.2 (12.3–14.1)
23.0 (21.9–24.1)
32.7 (31.5–33.9)
 EFW-M
13.1 (12.2–14.0)
18.0 (17.0–19.0)
26.2 (25.0–27.3)
 EFW-M plus MF
12.6 (11.7–13.5)
17.0 (16.0–18.0)
26.1 (25.0–27.3)
AC-M, AC MoM value at 33+0 ~ 39+6 weeks; EFW-M, EFW MoM value at 33+0 ~ 39+6 weeks; EFW-M plus MF, EFW-M plus maternal factors

Discussion

Main findings

The present study confirmed that the SGAp, which was constructed using ultrasound data obtained in the second and third trimesters along with data for maternal history of hypertension and preeclampsia, showed better screening ability than EFW. The AUCs of SGAp, AC-M, EFW-M, EFW-M plus MF, AC, AC growth velocity, EFW, and EFW plus MF for SGA neonate screening were 0.933 (95%CI: 0.916–0.950), 0.906 (95%CI: 0.887–0.925), 0.920 (95%CI: 0.903–0.936), 0.925 (95%CI: 0.909–0.941), 0.818 (95%CI: 0.791–0.845), 0.786 (95%CI: 0.752–0.821), 0.810 (95%CI: 0.782–0.838), and 0.834 (95%CI: 0.807–0.860), respectively. However, all eight measures (SGAp: 0.950, 95%CI: 0.932–0.967; AC-M: 0.929, 95%CI: 0.909–0.948; EFW-M: 0.938, 95%CI: 0.921–0.956; EFW-M plus MF: 0.941, 95%CI: 0.924–0.957; AC: 0.874, 95%CI: 0.847–0.900; AC growth velocity: 0.791, 95%CI: 0.746–0.837; EFW: 0.866, 95%CI: 0.839–0.893; EFW plus MF: 0.873, 95%CI: 0.847–0.899) showed more effective screening performance if birth occurred within two weeks of the assessment. The SGA screening efficiency of data transformed by MoM value was significantly higher than that of data without MoM value transformation.
The DR of SGAp, AC-M, EFW-M, and EFW-M plus MF at 10% FPR were 85.8%, 75.8%, 80.0%, and 82.5%, respectively for screening SGA neonates delivered < 2 weeks after the assessment. The FPR of SGA screening by SGAp for 85%, 90%, and 95% DR were 9.4%, 12.4%, and 22.0%, respectively, in deliveries occurring < 2 weeks after the assessment.
The DR of SGAp, AC-M, EFW-M, and EFW-M plus MF for birth at any time were 80.4%, 69.6%, 73.8%, and 74.3%, respectively. The FPR of SGA fetal screening by SGAp for 85%, 90%, and 95% DR were 11.8%, 16.4%, and 27.8%, respectively.

Strengths and limitations of the study

The strengths of this SGA neonatal screening study are as follows: First, based on the local median values for each GA, ultrasound data were MoM value-transformed, increasing their accuracy. Second, the study participants included pregnant women whose babies were born at 33–41 weeks (including preterm delivery). Third, the SGAp was based on prenatal ultrasound and maternal disease data, thereby ensuring better SGA screening than EFW.
The limitations of this study are as follows: First, this was a retrospective study. Of the 21092 pregnant women who gave birth in our hospital, 3/4 had been examined by ultrasound once or twice in our hospital, and most of them were tested in their local women's health care centers. Moreover, the ultrasound data were not incomplete in their local women's health care centers, resulting in a large amount of data loss. Second, the evaluations based on the SGAp model could only be performed after 33 weeks of gestation.

Comparison with the findings of previous studies

We found that EFW-M and EFW-M plus MF assessments in the third trimester could predict 73.8% and 74.3%, respectively, of SGA neonates delivered at 33–41 weeks’ gestation at 10% FPR. Fadigas et al. used EFW Z-score (EFW-Z) and EFW-Z plus MF data at 35–37 weeks and reported that 63.1% and 66.0% of SGA neonates (< 10th percentile) were screened at 10% FPR [20]. Ciobanu et al. also used EFW-Z obtained at 35+0 to 36+6 weeks of gestation for screening SGA neonates (< 10th percentile) and reported DR of 65.3% and 69.3% at 10% FPR for deliveries at ≥ 35 weeks’ gestation [21]. Bakalis et al. found that EFW-Z plus MF assessments at 30–34 weeks could predict 79.2% and 52.7% of SGA neonates with 10% FPR in deliveries occurring < 5 weeks and > 5 weeks after the assessments, respectively [16]. Overall, the screening effect of EFW-M was similar to that of the EFW-Z. However, it is easier to convert according to the GA.
This is the first study to combine ultrasound and MF data to construct an SGAp model. The SGAp model could screen 80.4% of SGA neonates at 10% FPR in deliveries at 33–41 weeks of gestation. For deliveries that occurred within two weeks of the evaluation, the DR increased up to 85.8%.

Implications for clinical practice

In China, it is common for pregnant women to undergo ultrasound examinations five times during pregnancy: at 6–8 weeks, 12–14 weeks, 23–25 weeks, 29–31 weeks, and 34–36 weeks. In addition, some pregnant women in the third trimester may undergo ultrasound examinations every month or even at two-week intervals. Appropriate use of these ultrasound data is extremely important. AC and EFW growth velocities between 20 and 36 weeks of gestation cannot be used for effective screening12. Therefore, in this study, the most effective ultrasonic data across different stages were superimposed, and a logistic regression model was used to establish the SGAp model. The screening performance of the SGAp model was shown to be better than that of EFW. The three ultrasound data points used in this study were all obtained over a relatively large gestational range, ranging from 20 to 27 weeks, 28 to 32 weeks, and 33 to 39 weeks, improving the convenience of performing SGAp-based assessments in actual clinical practice.

Conclusions

We aimed to evaluate the usefulness of the SGAp model for screening SGA neonates born at 33–41 weeks of gestation. The SGAp model could screen 80.4% of the SGA neonates at an FPR of 10%. The DR increased to 85.8% if the birth time was within two weeks of the assessment. Increasing the FPR further to 16.4% improved the SGA DR to 90% at any stage. Further research is needed to determine whether a larger sample size and more refined ultrasonic data can facilitate the establishment of a more accurate SGA screening tool.

Acknowledgements

Not applicable.

Declarations

This study was approved by the Ethics Committee of Taizhou Hospital of Zhejiang Province (approval number K20211218), and all patients provided informed consent in prenatal screening. All methods were performed in accordance with the relevant guidelines and regulations.
Not applicable.

Competing interests

The authors declare that they have no conflict of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Procas-Ramon B, Hierro-Espinosa C, Salim I, et al. The impact of individual sonographer variation on the detection of small for gestational age fetuses using a third trimester growth scan. J Clin Ultrasound. 2021;49:442–50.CrossRef Procas-Ramon B, Hierro-Espinosa C, Salim I, et al. The impact of individual sonographer variation on the detection of small for gestational age fetuses using a third trimester growth scan. J Clin Ultrasound. 2021;49:442–50.CrossRef
2.
Zurück zum Zitat Ishikawa T, Uchiyama H, Baba T, et al. The association between congenital heart disease and small for gestational age with regard to the prevalence and outcomes. Acta Paediatr. 2021;110:1009–16.CrossRef Ishikawa T, Uchiyama H, Baba T, et al. The association between congenital heart disease and small for gestational age with regard to the prevalence and outcomes. Acta Paediatr. 2021;110:1009–16.CrossRef
3.
Zurück zum Zitat Langhoff-Roos J, Lindmark G. Obstetric interventions and perinatal asphyxia in growth retarded term infants. Acta Obstet Gynecol Scand Suppl. 1997;165:39–43.PubMed Langhoff-Roos J, Lindmark G. Obstetric interventions and perinatal asphyxia in growth retarded term infants. Acta Obstet Gynecol Scand Suppl. 1997;165:39–43.PubMed
4.
Zurück zum Zitat Puga B, Puga PG, de Arriba A, et al. Psychomotor and intellectual development (Neurocognitive Function) of children born small for gestational age (SGA). Transversal and longitudinal study. Pediatr Endocrinol Rev. 2009;6:358–70.PubMed Puga B, Puga PG, de Arriba A, et al. Psychomotor and intellectual development (Neurocognitive Function) of children born small for gestational age (SGA). Transversal and longitudinal study. Pediatr Endocrinol Rev. 2009;6:358–70.PubMed
5.
Zurück zum Zitat Lundgren EM, Tuvemo T. Effects of being born small for gestational age on long-term intellectual performance. Best Pract Res Clin Endocrinol Metab. 2008;22:477–88.CrossRef Lundgren EM, Tuvemo T. Effects of being born small for gestational age on long-term intellectual performance. Best Pract Res Clin Endocrinol Metab. 2008;22:477–88.CrossRef
6.
Zurück zum Zitat Warshafsky C, Ronzoni S, Quaglietta P, et al. Comparison of sonographic fetal weight estimation formulas in patients with preterm premature rupture of membranes. BMC Pregnancy Childbirth. 2021;21:149.CrossRef Warshafsky C, Ronzoni S, Quaglietta P, et al. Comparison of sonographic fetal weight estimation formulas in patients with preterm premature rupture of membranes. BMC Pregnancy Childbirth. 2021;21:149.CrossRef
7.
Zurück zum Zitat Sovio U, Smith GCS. Comparison of estimated fetal weight percentiles near term for predicting extremes of birthweight percentile. Am J Obstet Gynecol. 2021;224(292):e1-292.e19. Sovio U, Smith GCS. Comparison of estimated fetal weight percentiles near term for predicting extremes of birthweight percentile. Am J Obstet Gynecol. 2021;224(292):e1-292.e19.
8.
Zurück zum Zitat Sánchez-Fernández M, Corral ME, Aceituno L, et al. Observer Influence with Other Variables on the Accuracy of Ultrasound Estimation of Fetal Weight at Term. Medicina (Kaunas). 2021;57:216.CrossRef Sánchez-Fernández M, Corral ME, Aceituno L, et al. Observer Influence with Other Variables on the Accuracy of Ultrasound Estimation of Fetal Weight at Term. Medicina (Kaunas). 2021;57:216.CrossRef
9.
Zurück zum Zitat Patel V, Resnick K, Liang C, et al. Midtrimester Ultrasound Predictors of Small-for-Gestational-Age Neonates. J Ultrasound Med. 2020;39:2027–31.CrossRef Patel V, Resnick K, Liang C, et al. Midtrimester Ultrasound Predictors of Small-for-Gestational-Age Neonates. J Ultrasound Med. 2020;39:2027–31.CrossRef
10.
Zurück zum Zitat Erkamp JS, Voerman E, Steegers EAP, et al. Second and third trimester fetal ultrasound population screening for risks of preterm birth and small-size and large-size for gestational age at birth: a population-based prospective cohort study. BMC Med. 2020;18:63.CrossRef Erkamp JS, Voerman E, Steegers EAP, et al. Second and third trimester fetal ultrasound population screening for risks of preterm birth and small-size and large-size for gestational age at birth: a population-based prospective cohort study. BMC Med. 2020;18:63.CrossRef
11.
Zurück zum Zitat Ciobanu A, Formuso C, Syngelaki A, et al. Prediction of small-for-gestational-age neonates at 35–37 weeks’ gestation: contribution of maternal factors and growth velocity between 20 and 36 weeks. Ultrasound Obstet Gynecol. 2019;53:488–95.CrossRef Ciobanu A, Formuso C, Syngelaki A, et al. Prediction of small-for-gestational-age neonates at 35–37 weeks’ gestation: contribution of maternal factors and growth velocity between 20 and 36 weeks. Ultrasound Obstet Gynecol. 2019;53:488–95.CrossRef
12.
Zurück zum Zitat Leavitt K, Odibo L, Nwabuobi C, et al. The value of introducing cerebroplacental ratio (CPR) versus umbilical artery (UA) Doppler alone for the prediction of neonatal small for gestational age (SGA) and short-term adverse outcomes. J Matern Fetal Neonatal Med. 2021;34:1565–9.CrossRef Leavitt K, Odibo L, Nwabuobi C, et al. The value of introducing cerebroplacental ratio (CPR) versus umbilical artery (UA) Doppler alone for the prediction of neonatal small for gestational age (SGA) and short-term adverse outcomes. J Matern Fetal Neonatal Med. 2021;34:1565–9.CrossRef
13.
Zurück zum Zitat Finneran MM, Ware CA, Russo J, et al. Use of birth weight- vs. ultrasound-derived fetal weight classification methods: implications for detection of abnormal umbilical artery Doppler. J Perinat Med. 2020;48:615–24.CrossRef Finneran MM, Ware CA, Russo J, et al. Use of birth weight- vs. ultrasound-derived fetal weight classification methods: implications for detection of abnormal umbilical artery Doppler. J Perinat Med. 2020;48:615–24.CrossRef
14.
Zurück zum Zitat Birdir C, Fryze J, Frölich S, et al. Impact of maternal serum levels of Visfatin, AFP, PAPP-A, sFlt-1 and PlGF at 11–13 weeks gestation on small for gestational age births. J Matern Fetal Neonatal Med. 2017;30:629–34.CrossRef Birdir C, Fryze J, Frölich S, et al. Impact of maternal serum levels of Visfatin, AFP, PAPP-A, sFlt-1 and PlGF at 11–13 weeks gestation on small for gestational age births. J Matern Fetal Neonatal Med. 2017;30:629–34.CrossRef
15.
Zurück zum Zitat Boonpiam R, Wanapirak C, Sirichotiyakul S, et al. Quad test for fetal aneuploidy screening as a predictor of small-for-gestational age fetuses: a population-based study. BMC Pregnancy Childbirth. 2020;20:621.CrossRef Boonpiam R, Wanapirak C, Sirichotiyakul S, et al. Quad test for fetal aneuploidy screening as a predictor of small-for-gestational age fetuses: a population-based study. BMC Pregnancy Childbirth. 2020;20:621.CrossRef
16.
Zurück zum Zitat Bakalis S, Gallo DM, Mendez O, et al. Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30–34 weeks. Ultrasound Obstet Gynecol. 2015;46:208–15.CrossRef Bakalis S, Gallo DM, Mendez O, et al. Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30–34 weeks. Ultrasound Obstet Gynecol. 2015;46:208–15.CrossRef
17.
Zurück zum Zitat Vijayram R, Damaraju N, Xavier A, et al. Comparison of first trimester dating methods for gestational age estimation and their implication on preterm birth classification in a North Indian cohort. BMC Pregnancy Childbirth. 2021;21:343.CrossRef Vijayram R, Damaraju N, Xavier A, et al. Comparison of first trimester dating methods for gestational age estimation and their implication on preterm birth classification in a North Indian cohort. BMC Pregnancy Childbirth. 2021;21:343.CrossRef
18.
Zurück zum Zitat Kim MA, Han GH, Kim YH. Prediction of small-for-gestational age by fetal growth rate according to gestational age. PLoS ONE. 2019;14: e0215737.CrossRef Kim MA, Han GH, Kim YH. Prediction of small-for-gestational age by fetal growth rate according to gestational age. PLoS ONE. 2019;14: e0215737.CrossRef
19.
Zurück zum Zitat Capital Institute of Pediatrics; Coordinating Study Group of Nine Cities on the Physical Growth and Development of Children. Growth standard curves of birth weight, length and head circumference of Chinese newborns of different gestation. Zhonghua Er Ke Za Zhi. 2020; 58: 738–746. Capital Institute of Pediatrics; Coordinating Study Group of Nine Cities on the Physical Growth and Development of Children. Growth standard curves of birth weight, length and head circumference of Chinese newborns of different gestation. Zhonghua Er Ke Za Zhi. 2020; 58: 738–746.
20.
Zurück zum Zitat Fadigas C, Saiid Y, Gonzalez R, et al. Prediction of small-for-gestational-age neonates: screening by fetal biometry at 35–37 weeks. Ultrasound Obstet Gynecol. 2015;45:559–65.CrossRef Fadigas C, Saiid Y, Gonzalez R, et al. Prediction of small-for-gestational-age neonates: screening by fetal biometry at 35–37 weeks. Ultrasound Obstet Gynecol. 2015;45:559–65.CrossRef
21.
Zurück zum Zitat Ciobanu A, Anthoulakis C, Syngelaki A, et al. Prediction of small-for-gestational-age neonates at 35–37 weeks’ gestation: contribution of maternal factors and growth velocity between 32 and 36 weeks. Ultrasound Obstet Gynecol. 2019;53:630–7.CrossRef Ciobanu A, Anthoulakis C, Syngelaki A, et al. Prediction of small-for-gestational-age neonates at 35–37 weeks’ gestation: contribution of maternal factors and growth velocity between 32 and 36 weeks. Ultrasound Obstet Gynecol. 2019;53:630–7.CrossRef
Metadaten
Titel
Prediction of small-for-gestational-age neonates at 33–39 weeks’ gestation in China: logistic regression modeling of the contributions of second- and third-trimester ultrasound data and maternal factors
verfasst von
Danping Xu
Xiuzhen Shen
Heqin Guan
Yiyang Zhu
Minchan Yan
Xiafang Wu
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
BMC Pregnancy and Childbirth / Ausgabe 1/2022
Elektronische ISSN: 1471-2393
DOI
https://doi.org/10.1186/s12884-022-04991-7

Weitere Artikel der Ausgabe 1/2022

BMC Pregnancy and Childbirth 1/2022 Zur Ausgabe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.